Cambiar Investors LLC lowered its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 4.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,361,608 shares of the company's stock after selling 70,900 shares during the quarter. Cambiar Investors LLC's holdings in Haleon were worth $14,011,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the company. American Century Companies Inc. increased its position in Haleon by 4.3% in the first quarter. American Century Companies Inc. now owns 750,654 shares of the company's stock worth $7,724,000 after purchasing an additional 30,764 shares during the period. Kovitz Investment Group Partners LLC grew its position in shares of Haleon by 29.8% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 13,867 shares of the company's stock worth $143,000 after buying an additional 3,184 shares during the period. Vestmark Advisory Solutions Inc. raised its stake in shares of Haleon by 60.2% during the first quarter. Vestmark Advisory Solutions Inc. now owns 99,997 shares of the company's stock worth $1,029,000 after buying an additional 37,577 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in Haleon by 9.1% in the first quarter. Neuberger Berman Group LLC now owns 1,047,009 shares of the company's stock valued at $10,774,000 after buying an additional 87,116 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Haleon by 1,551.2% in the first quarter. Caitong International Asset Management Co. Ltd now owns 12,516 shares of the company's stock valued at $129,000 after acquiring an additional 11,758 shares during the last quarter. Institutional investors own 6.67% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently commented on HLN. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Finally, BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and an average price target of $12.33.
View Our Latest Research Report on HLN
Haleon Stock Up 1.7%
Shares of NYSE:HLN traded up $0.1650 during midday trading on Wednesday, reaching $9.9050. 7,950,440 shares of the company were exchanged, compared to its average volume of 12,943,433. The stock has a fifty day simple moving average of $9.99 and a two-hundred day simple moving average of $10.21. The firm has a market cap of $44.46 billion, a PE ratio of 25.40, a P/E/G ratio of 2.86 and a beta of 0.23. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42.
Haleon Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Stockholders of record on Friday, August 15th will be given a $0.0555 dividend. This is a boost from Haleon's previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. Haleon's payout ratio is presently 28.21%.
Haleon Company Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.